<?xml version="1.0" encoding="UTF-8"?>
<p id="Par28">Shenfu combined with antibiotic treatment can shorten the time of fever, cough, and lung rales in patients with severe pneumonia, reduce the content of soluble E-selection (s E-selection) and von Willebrand factor (vWF), and improve the function of vascular endothelial cells, while reducing myocardial damage, and enhance blood gas and respiratory indicators [
 <xref ref-type="bibr" rid="CR54">54</xref>]. Shenfu can significantly improve the mean arterial pressure, cardiac index, extravascular lung water index, and other hemodynamic indexes in patients with severe pneumonia [
 <xref ref-type="bibr" rid="CR55">55</xref>]. It can additionally inhibit the HMGB1/NF-κB signaling pathway, thereby reducing the expression of pro-inflammatory cytokines TNF-α and IL-1β, preventing the occurrence of cytokine storms [
 <xref ref-type="bibr" rid="CR56">56</xref>, 
 <xref ref-type="bibr" rid="CR57">57</xref>]. However, there are no reported clinical studies in the COVID-19 treatment. Currently, Shenfu is recommended for treating patients in the progressive stage of COVID-19 (critical case) in the NHC guidelines [
 <xref ref-type="bibr" rid="CR6">6</xref>].
</p>
